Not provided
Not provided
Not provided
Not provided
Not provided
Behind enrollment targets
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Obstructive sleep apnea (OSA) is highly prevalent among Veterans, and is associated with significant mortality and multiple morbidities. Available treatments have had limited effectiveness in treating OSA and alleviating associated morbidity. The investigators' previous research found a reduction in OSA severity of approximately 25% following modest exercise training. That this effect occurred independent of weight loss raises the exciting possibility that exercise combined with weight loss could reduce OSA by at least 50% and have unique health benefits for OSA patients. Following screening and baseline assessments, 90 overweight Veterans ages 18-60 years with OSA will be randomized to one of three 16-week treatments: (1) exercise training; (2) 10 % weight loss; and 3) exercise + weight loss. Changes in OSA and related morbidity will be compared between treatments.
Rationale: Approximately 15-20% of adults have obstructive sleep apnea (OSA), and evidence indicates that the prevalence of OSA is perhaps twice as high among Veterans. OSA has been clearly linked to increased mortality and multiple morbidities, and undoubtedly contributes to the high prevalence of health problems among Veterans. Current treatments for OSA are not well tolerated, often have limited efficacy, and often do not result in improvements in health. The investigators' recent research demonstrated that 12 weeks of moderate exercise training elicited a reduction of OSA of ~25%, as well as significant improvement in mood, fatigue, quality of life, and cardiovascular health. Interestingly, as with other health benefits of exercise, the investigators' research is consistent with other research showing that exercise can reduce OSA independent of changes in body weight. These studies raise the exciting possibility that exercise training combined with modest weight loss could elicit a chronic reduction in OSA of 50% or more.
Objectives: The investigators' Objective is to compare the effects of 16 weeks of exercise training alone, weight loss alone, and exercise + weight loss on OSA severity and associated morbidity.
Methods: Following extensive screening and baseline assessment, N=90 overweight/obese Veterans (ages 18-60 years) with mild to severe OSA will be randomized to one of three 16-week treatments. (1) Exercise Alone (n=30) will involve training 4 days per week under supervision of a clinical exercise physiologist. It will include aerobic exercise (treadmill, cycling, elliptical) that will gradually increase to 30-45 min on 4 days/wk, as well as resistance exercise (15 min) on 2 days/week. (2) Weight Loss Alone (n=30) will involve a structured meal plan (including some meal replacement with shakes or bars), and weekly counseling designed to elicit a reduction in body weight of 10%. (3) Exercise + Weight Loss (n=30) will involve the same exercise and weight loss interventions as in the other treatments. Outside of the interventions, participants will be asked to maintain their usual exercise and diet habits, as verified, respectively, with actigraphic recording and a 24-hr food recall. Before and after the treatments, participants will undergo 5 days/nights of home-based actigraphic and diary-assessed sleep, and one night of laboratory polysomnographic recording of sleep, including OSA severity. Comorbidity measures will include pre- to post-treatment changes in blood pressure, glucose, insulin, lipids, hemoglobin a1c, body weight/composition, and inflammation (e.g., CRP, IL-6). Also measured will be monthly changes in self-reports of sleep quality, functional outcomes of sleepiness (FOSQ), and snoring symptoms. A 3-month follow-up will include home assessment of OSA, as well as sleep quality, FOSQ, and snoring. Mediation analysis will explore whether improvements in OSA are mediated by changes in percent of deep sleep, body weight, trunk body fat percent, trunk total mass, respiratory muscle strength, and upper airway obstruction assessed in the laboratory.
Implications for Future Research. Demonstration of a reduction of OSA by 50% would result in extensive subsequent studies. These would likely include studies of dose-response effects; comparisons of different modes of exercise; studies of the feasibility of telemedicine approaches to the interventions; comparative efficacy studies vs. PAP; further mechanistic studies, for example, of upper airway collapsibility and composition (e.g, via MRI); and studies of other positive health outcomes, such as extensive heart imaging.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Exercise | Experimental | 16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week |
|
| Weight Loss | Experimental | 16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement |
|
| Exercise + Weight Loss | Experimental | Combined components of the exercise and weight loss treatments |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exercise | Behavioral | 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise) |
| Measure | Description | Time Frame |
|---|---|---|
| Apnea-hypopnea Index (AHI) | Common criterion for obstructive sleep apnea: number of apnea and hypopnea episodes per hour of sleep. Baseline-end - positive value indicates a reduction. | Change from baseline to the end of the study (16-week intervention) |
| Measure | Description | Time Frame |
|---|---|---|
| Functional Outcomes of Sleepiness Questionnaire (FOSQ) | Measures impairments in functioning associated with sleepiness. Baseline minus end of study value. Positive value indicates improvement; negative value indicates worsening. Minimum score on scale: 0 Maximum score: 120 | Change from baseline to the end of the study (16-week intervention) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shawn D. Youngstedt, PhD | Phoenix VA Health Care System, Phoenix, AZ | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Phoenix VA Health Care System, Phoenix, AZ | Phoenix | Arizona | 85012 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Reasons for not passing screening procedures for various reasons, including insufficiently severe sleep apnea. Of the 47 participants who started one of the treatments, 24 dropped out during the study, for various reasons, including burden of the intervention, transportation difficulties, going to jail. Six other participants were excluded for non-adherence. Thus, 17 participants completed the study.
83 signed consent. Of these, 31 did not pass screening for various reasons, and 5 participants were not able to complete screening procedures after the study was stopped. Thus, 47 participants were randomized to one of the three treatments
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Weight Loss | 16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement Weight Loss: 16 week. the goal is 10% weight loss. |
| FG001 | Exercise | 16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week Exercise: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise) |
| FG002 | Exercise + Weight Loss | Combined components of the exercise and weight loss treatments Exercise + Weight Loss: Combined exercise and weight loss components of the other arms |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Information on those who started the intervention
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Weight Loss | 16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement Weight Loss: 16 week. the goal is 10% weight loss. |
| BG001 | Exercise |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Apnea-hypopnea Index (AHI) | Common criterion for obstructive sleep apnea: number of apnea and hypopnea episodes per hour of sleep. Baseline-end - positive value indicates a reduction. | Data on the final AHI are missing for one participants in the exercise + weight loss treatment. | Posted | Mean | Standard Deviation | events per hour | Change from baseline to the end of the study (16-week intervention) |
|
2 years
VA procedures
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Weight Loss | 16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement Weight Loss: 16 week. the goal is 10% weight loss. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| David Thompson | VA | 602-496-0242 | david.thompson4@va.gov |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 4, 2016 | Oct 1, 2020 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D050177 | Overweight |
| D009043 | Motor Activity |
| D015431 | Weight Loss |
| D012891 | Sleep Apnea Syndromes |
| ID | Term |
|---|---|
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Weight Loss | Behavioral | 16 week. the goal is 10% weight loss. |
|
| Exercise + Weight Loss | Behavioral | Combined exercise and weight loss components of the other arms |
|
| Snoring Severity Scale | Questionnaire that measures severity of snoring with a questionnaire. A positive value indicates improvement; a negative value indicates worsening. Minimum score: 0 Maximum score: 9 | Change from baseline to the end of the study (16-week intervention) |
| Pittsburgh Sleep Quality Index (PSQI) | Commonly used metric of sleep quality. Baseline minus end of study. Positive value indicates improvement. Minimum score: 0 Maximum score: 21 | Change from baseline to the end of the study (16-week intervention) |
| Blood Pressure | Blood pressure | Change from baseline to the end of the study (16-week intervention) |
| Body Weight | Fasting body weight. Weight change (kg) beginning to end of study (positive valuate = decrease) | Change from baseline to the end of the study (16-week intervention) |
| Percent Body Fat Assessed With Dual-energy X-reay Absorptiometry (DEXA) | Percent body fat assessed with DEXA. Change in percent body fat - positive value represents a decrease. | Change from baseline to the end of the study (16-week intervention) |
| C-reactive Protein (CRP) | Measure of inflammation | Change from baseline to the end of the study (16-week intervention) |
16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week Exercise: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise) |
| BG002 | Exercise + Weight Loss | Combined components of the exercise and weight loss treatments Exercise + Weight Loss: Combined exercise and weight loss components of the other arms |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
Exercise: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
| OG002 | Exercise + Weight Loss | Combined components of the exercise and weight loss treatments Exercise + Weight Loss: Combined exercise and weight loss components of the other arms |
|
|
| Secondary | Functional Outcomes of Sleepiness Questionnaire (FOSQ) | Measures impairments in functioning associated with sleepiness. Baseline minus end of study value. Positive value indicates improvement; negative value indicates worsening. Minimum score on scale: 0 Maximum score: 120 | Posted | Mean | Standard Deviation | units on a scale | Change from baseline to the end of the study (16-week intervention) |
|
|
|
| Secondary | Snoring Severity Scale | Questionnaire that measures severity of snoring with a questionnaire. A positive value indicates improvement; a negative value indicates worsening. Minimum score: 0 Maximum score: 9 | Posted | Mean | Standard Deviation | units on a scale | Change from baseline to the end of the study (16-week intervention) |
|
|
|
| Secondary | Pittsburgh Sleep Quality Index (PSQI) | Commonly used metric of sleep quality. Baseline minus end of study. Positive value indicates improvement. Minimum score: 0 Maximum score: 21 | Posted | Mean | Standard Deviation | units on a scale | Change from baseline to the end of the study (16-week intervention) |
|
|
|
| Secondary | Blood Pressure | Blood pressure | Data missing | Posted | Change from baseline to the end of the study (16-week intervention) |
|
|
| Secondary | Body Weight | Fasting body weight. Weight change (kg) beginning to end of study (positive valuate = decrease) | Final body weight data are missing on n=1, 3, and 2 participants in the weight loss, exercise, and exercise + weight loss treatment, respectively. | Posted | Mean | Standard Deviation | kg | Change from baseline to the end of the study (16-week intervention) |
|
|
|
| Secondary | Percent Body Fat Assessed With Dual-energy X-reay Absorptiometry (DEXA) | Percent body fat assessed with DEXA. Change in percent body fat - positive value represents a decrease. | Data are missing for n=2, 3, and 2 participants in the weight loss, exercise, and exercise + weight loss treatments, respectively. | Posted | Mean | Standard Deviation | change in % body fat | Change from baseline to the end of the study (16-week intervention) |
|
|
|
| Secondary | C-reactive Protein (CRP) | Measure of inflammation | Unable to locate data | Posted | Change from baseline to the end of the study (16-week intervention) |
|
|
| 0 |
| 14 |
| 0 |
| 14 |
| 0 |
| 14 |
| EG001 | Exercise | 16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week Exercise: 16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise) | 0 | 16 | 0 | 16 | 0 | 16 |
| EG002 | Exercise + Weight Loss | Combined components of the exercise and weight loss treatments Exercise + Weight Loss: Combined exercise and weight loss components of the other arms | 0 | 17 | 0 | 17 | 0 | 17 |
Not provided
Not provided
| D020920 |
| Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
| D001836 | Body Weight Changes |